The DOI matches its Crossref record; 155 of the 156 references it cites were found in a registry or an index.
Molecular and cellular insights into T cell exhaustion
Open accessAbstract
In chronic infections and cancer, T cells are exposed to persistent antigen and/or inflammatory signals. This scenario is often associated with the deterioration of T cell function: a state called 'exhaustion'. Exhausted T cells lose robust effector functions, express multiple inhibitory receptors and are defined by an altered transcriptional programme. T cell exhaustion is often associated with inefficient control of persisting infections and tumours, but revitalization of exhausted T cells can reinvigorate immunity. Here, we review recent advances that provide a clearer molecular understanding of T cell exhaustion and reveal new therapeutic targets for persisting infections and cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other situations of chronic antigen stimulation, such as cancer or chronic viral infections, result in T cell exhaustion, characterized by the progressive loss of cytokine expression, proliferative potential, and upregulation of inhibitory receptors (immune checkpoints).”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“Exhaustion can be partially reversed by immune checkpoint inhibitors, providing the basis for successful therapies against cancer. 32,33”
From Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases (2024) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“In TME, prolonged antigen exposure leads to T cell exhaustion, marked by losing effector functions.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [24]
In the citing paper
“cells with an exhaustion signature (denoted exhausted, fig. S3B) overexpressing the Lag3, Tbc1d4, Sostdc1, and Tnfsf8 genes (22, 31)”
From Aging promotes reorganization of the CD4 T cell landscape toward extreme regulatory and effector phenotypes (2019) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Self-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Self-citationRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Self-citationControl of Viremia in Simian Immunodeficiency Virus Infection by CD8 + Lymphocytes
Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Rácz, P., Tenner‐Racz, K., Dalesandro, M. R., Scallon, B. J., et al. (1999) · Science · doi:10.1126/science.283.5403.857 · Cited by 2,167
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Self-citation
Flagged first, then by citations
1 of the 156 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 1,019
Muñoz, L. E., Huang, L., Bommireddy, R., Sharma, R., Monterroza, L., Guin, R. N., Samaranayake, S. G., Pack, C. D., Ramachandiran, S., Reddy, S. J. C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002614 · Cited by 68
Shao, M., Teng, X., Guo, X., Zhang, H., Huang, Y., Cui, J., Si, X., Ding, L., Wang, X., Li, X., et al. (2022) · Advanced Science · doi:10.1002/advs.202103508 · Cited by 67
Impact of epigenetic reprogramming on antitumor immune responses in glioma
McClellan, B. L., Haase, S., Núñez, F. J., Alghamri, M. S., Dabaja, A. A., Lowenstein, P. R., & Castro, M. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163450 · Cited by 68
Role of regulation of PD-1 and PD-L1 expression in sepsis
Zhang, T., Yu-Jing, L., & Ma, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1029438 · Cited by 75
Ahn, T., Bae, E., & Seo, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.004 · Cited by 71
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 68
Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes
Yeo, L., Woodwyk, A., Sood, S., Lorenc, A., Eichmann, M., Pujol‐Autonell, I., Melchiotti, R., Skowera, A., Fidanis, E., Dolton, G. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120555 · Cited by 68
Newman, J. L., & Stone, J. R. (2019) · Cardiovascular Pathology · doi:10.1016/j.carpath.2019.107148 · Cited by 66
PD1 pathway in immune-mediated myopathies
Knauß, S., Preuße, C., Allenbach, Y., Léonard-Louis, S., Touat, M., Fischer, N., Radbruch, H., Mothes, R., Matyash, V., Boehmerle, W., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000558 · Cited by 66
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 65
Unraveling exhaustion in adaptive and conventional NK cells
Merino, A. M., Kim, H., Miller, J. S., & Cichocki, F. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0620-091r · Cited by 65
Short telomeres increase the risk of severe COVID-19
Froidure, A., Mahieu, M., Hoton, D., Laterre, P., Yombi, J. C., Koenig, S., Ghaye, B., Defour, J., & Decottignies, A. (2020) · Aging · doi:10.18632/aging.104097 · Cited by 69
Recent advances in biomaterial-boosted adoptive cell therapy
Xue, Y., Che, J., Ji, X., Li, Y., Xie, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00786f · Cited by 70
Bazioti, V., La Rose, A. M., Maassen, S., Bianchi, F., de Boer, R., Halmos, B., Dabral, D., Guilbaud, E., Flohr-Svendsen, A., Groenen, A. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31135-4 · Cited by 65
BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
Zhong, M., Gao, R., Zhao, R., Huang, Y., Chen, C., Li, K., Yu, X., Nie, D., Chen, Z., Liu, X., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05123-x · Cited by 64
A close-up on the expanding landscape of CD21–/low B cells in humans
Gjertsson, I., McGrath, S., Grimstad, K., Jonsson, C. A., Camponeschi, A., Thorarinsdottir, K., & Mårtensson, I. (2022) · Clinical & Experimental Immunology · doi:10.1093/cei/uxac103 · Cited by 71
Topchyan, P., Lin, S., & Cui, W. (2023) · Immune Network · doi:10.4110/in.2023.23.e41 · Cited by 73
He, J., Zhou, Y. L., & Sun, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01438-0 · Cited by 77
PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
Tamura, H., Ishibashi, M., Sunakawa-Kii, M., & Inokuchi, K. (2020) · Cancers · doi:10.3390/cancers12040924 · Cited by 67
Audrito, V., Managò, A., Gaudino, F., Sorci, L., Messana, V. G., Raffaelli, N., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01720 · Cited by 67
Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients
Hartzell, S., Bin, S., Benedetti, C., Haverly, M., Gallon, L. G., Zaza, G., Riella, L. V., Menon, M. C., Florman, S. S., Rahman, A. H., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.16261 · Cited by 64
Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients
Basse, C., Diakite, S., Servois, V., Frélaut, M., Noret, A., Bellesœur, A., Moreau, P., Massiani, M.-A., Bouyer, A.-S., Vuagnat, P., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa090 · Cited by 64
Wang, Y., Xu, C., Meng, M., Lin, L., Hu, Y., Hao, K., Shu, S., Zhang, S., Wu, J., Liu, F., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101266 · Cited by 64
Lombardi, A., Villa, S., Castelli, V., Bandera, A., & Gori, A. (2021) · Microorganisms · doi:10.3390/microorganisms9122460 · Cited by 63
Liu, L., Cheng, X., Yang, H., Lian, S., Jiang, Y., Liang, J., Chen, X., Mo, S., Shi, Y., Zhao, S., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01516-w · Cited by 68
IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?
Belfiore, A., Rapicavoli, R. V., Moli, R. L., Lappano, R., Morrione, A., Francesco, E. M. D., & Vella, V. (2023) · Biomedicines · doi:10.3390/biomedicines11010229 · Cited by 66
Lv, Y., Li, M., Weng, L., Huang, H., Mao, Y., Yang, D. A., Wei, Q., Zhao, M., Qin, W. D., Rui, K., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02888-7 · Cited by 69
CD4 + T and CD8 + T Cells in Uterus Exhibit Both Selective Dysfunction and Residency Signatures
Kang, S., Jin, S., Mao, X., He, B., & Wu, C. Y. (2024) · Journal of Immunology Research · doi:10.1155/2024/5582151 · Cited by 64
Perturbed CD8+ T cell immunity across universal influenza epitopes in the elderly
Nguyen, T. H. O., Sant, S. A., Bird, N. L., Grant, E. J., Clemens, E. B., Koutsakos, M., Valkenburg, S. A., Gras, S., Lappas, M., Jaworowski, A., et al. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ma0517-207r · Cited by 64
Memarnejadian, A., Meilleur, C. E., Shaler, C. R., Khazaie, K., Bennink, J. R., Schell, T. D., & Haeryfar, S. M. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700643 · Cited by 65
Lu, S., Concha‐Benavente, F., Shayan, G., Srivastava, R. M., Gibson, S. P., Wang, L., Gooding, W. E., & Ferris, R. L. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.01.019 · Cited by 65
HCV-Specific T Cell Responses During and After Chronic HCV Infection
Luxenburger, H., Neumann-Haefelin, C., Thimme, R., & Boettler, T. (2018) · Viruses · doi:10.3390/v10110645 · Cited by 64
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features
Porcu, M., Silva, P. D., Solinas, C., Battaglia, A., Schena, M., Scartozzi, M., Bron, D., Suri, J. S., Willard-Gallo, K. E., Sangiolo, D., et al. (2019) · Cancers · doi:10.3390/cancers11030305 · Cited by 64
Patil, N. K., Luan, L., Bohannon, J. K., Hernandez, A., Guo, Y., & Sherwood, E. R. (2017) · Journal of Leukocyte Biology · doi:10.1002/jlb.5hi0917-360r · Cited by 63
Xu, R., Wu, J., Zhang, X., Zou, X., Li, C., Wang, H., Yuan, M., Chen, M., Sun, Q., & Liu, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104623 · Cited by 64
Vonwirth, V., Bülbül, Y., Werner, A., Echchannaoui, H., Windschmitt, J., Habermeier, A., Ioannidis, S., Shin, N., Conradi, R., Bros, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.617699 · Cited by 63
Scott, J. I., Mendive‐Tapia, L., Gordon, D., Barth, N. D., Thompson, E. J., Cheng, Z., Taggart, D., Kitamura, T., Bravo‐Blas, A., Roberts, E. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29691-w · Cited by 65
Hiltbrunner, S., Cords, L., Kasser, S., Freiberger, S. N., Kreutzer, S., Toussaint, N. C., Grob, L., Opitz, I., Messerli, M., Zoche, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40745-5 · Cited by 78
Luan, X., Lei, T., Fang, J., Liu, X., Fu, H., Li, Y., Chu, W., Jiang, P., Tong, C., Qi, H., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.12.010 · Cited by 63
Kraja, F., Jurišić, V., Hromić-Jahjefendić, A., Rossopoulou, N., Κάτσιλα, Θ., Martinović, K. M., Rivas, J. D. L., Diaconu, C. C., & Szöőr, Á. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1601773 · Cited by 71
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 78
Tomov, V. T., Palko, O., Lau, C. W., Pattekar, A., Sun, Y., Tacheva, R., Bengsch, B., Manne, S., Cosma, G. L., Eisenlohr, L. C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.017 · Cited by 63
Self-citationOvercoming immune tolerance in chronic hepatitis B by therapeutic vaccination
Dembek, C. J., Protzer, U., & Roggendorf, M. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.04.003 · Cited by 63
Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology
Caliendo, F., Dukhinova, M., & Siciliano, V. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00043 · Cited by 65
Exhausted and Senescent T Cells at the Maternal-Fetal Interface in Preterm and Term Labor
Slutsky, R., Romero, R. J., Xu, Y., Galaz, J., Miller, D., Done, B., Tarca, A. L., Gregor, S., Hassan, S. S., Leng, Y., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/3128010 · Cited by 62
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Borst, J. G., Busselaar, J., Bosma, D. M. T., & OSSENDORP, F. A. (2021) · European Journal of Immunology · doi:10.1002/eji.202048994 · Cited by 66
CD8+ T Cell Senescence: Lights and Shadows in Viral Infections, Autoimmune Disorders and Cancer
Tedeschi, V., Paldino, G., Kunkl, M., Paroli, M., Sorrentino, R., Tuosto, L., & Fiorillo, M. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063374 · Cited by 65
Papadatos-Pastos, D., Yuan, W., Pal, A., Crespo, M., Ferreira, A., Gürel, B., Prout, T., Ameratunga, M., Chénard-Poirier, M., Curcean, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004495 · Cited by 60
The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment
Luu, M., Schütz, B., Lauth, M., & Visekruna, A. (2023) · Cancers · doi:10.3390/cancers15051588 · Cited by 65
Costimulatory domains direct distinct fates of CAR-driven T cell dysfunction
Selli, M. E., Landmann, J. H., Terekhova, M., Lattin, J., Heard, A. D., Hsu, Y.-S., Chang, T.-C., Chang, J., Warrington, J. M., Ha, H., et al. (2023) · Blood · doi:10.1182/blood.2023020100 · Cited by 63
The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
Föhse, K., Geckin, B., Zoodsma, M., Kılıç, G., Liu, Z., Röring, R. J., Overheul, G. J., van de Maat, J., Bulut, O. P., Hoogerwerf, J. J., et al. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109762 · Cited by 64
Qiu, K., Duan, X., Mao, M., Song, Y., Rao, Y., Cheng, D., Feng, L., Shao, X., Jiang, C., Huang, H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00733-8 · Cited by 63
Ma, S., Ong, L.-T., Jiang, Z., Lee, W. C., Lee, P. L., Yusuf, M., Ditzel, H. J., Wang, Y., Chen, Q., Wang, W., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.12.001 · Cited by 62
Dammeijer, F. F., Lau, S. P., van Eijck, C. H. J., van der Burg, S. H., & Aerts, J. G. J. V. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.011 · Cited by 66
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma
Schadendorf, D., Nghiem, P., Bhatia, S., Hauschild, A., Saïag, P., Mahnke, L. A., Hariharan, S., & Kaufman, H. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338237 · Cited by 66
Magen, A., Nie, J., Ciucci, T., Tamoutounour, S., Zhao, Y., Mehta, M., Tran, B. Q., McGavern, D. B., Hannenhalli, S. S., & Bosselut, R. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.131 · Cited by 63
Prospects and challenges for use of CAR T cell therapies in solid tumors
Ramakrishna, S., Barsan, V. V., & Mackall, C. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738378 · Cited by 62
Lum, L. G., Thakur, A. B., Choi, M., Deol, A., Kondadasula, S. V., Schalk, D. L., Fields, K., Dufrense, M., Philip, P., Dyson, G. E., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1773201 · Cited by 64
Cancer metabolism and intervention therapy
Zhao, H., & Li, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00012-1 · Cited by 67
An Update on Immune Checkpoint Therapy for the Treatment of Lynch Syndrome
Therkildsen, C., Jensen, L. H., Rasmussen, M., & Bernstein, I. (2021) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s278054 · Cited by 61
Shahbaz, S., Xu, L., Sligl, W., Osman, M. S., Bozorgmehr, N., Mashhouri, S., Redmond, D., Rosero, E. P., Walker, J. W. T., & Elahi, S. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100446 · Cited by 63
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
Paderi, A., Fancelli, S., Caliman, E., Pillozzi, S., Gambale, E., Mela, M. M., Doni, L., Mazzoni, F., & Antonuzzo, L. (2021) · Current Oncology · doi:10.3390/curroncol28050283 · Cited by 62
Li, J., Huang, D., Cheng, R., Figueiredo, P., Fontana, F., Correia, A., Wang, S., Liu, Z., Kemell, M., Torrieri, G., et al. (2021) · Advanced Materials · doi:10.1002/adma.202108012 · Cited by 61
Melese, E. S., Franks, E., Cederberg, R. A., Harbourne, B., Shi, R., Wadsworth, B. J., Collier, J. L., Halvorsen, E. C., Johnson, F. D., Luu, J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2010905 · Cited by 62
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61
Guo, H., Zhang, W., Wang, L., Shao, Z., & Huang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121821 · Cited by 61
Prospects and challenges of CAR-T cell therapy combined with ICIs
Lv, Y., Luo, X., Xie, Z., Qiu, J.-Y., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., & Zuo, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1368732 · Cited by 62
Minnie, S. A., Waltner, O. G., Zhang, P., Takahashi, S., Nemychenkov, N. S., Ensbey, K. S., Schmidt, C. R., Legg, S. R. W., Comstock, M., Boiko, J. R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adg1094 · Cited by 58
Transient stimulation expands superior antitumor T cells for adoptive therapy
Kagoya, Y., Nakatsugawa, M., Ochi, T., Cen, Y., Guo, T., Anczurowski, M., Saso, K., Butler, M. O., & Hirano, N. (2017) · JCI Insight · doi:10.1172/jci.insight.89580 · Cited by 61
Tracking the fate and origin of clinically relevant adoptively transferred CD8 + T cells in vivo
Chapuis, A. G., Desmarais, C., Emerson, R., Schmitt, T. M., Shibuya, K. C., Lai, I. P., Wagener, F. D., Chou, J., Roberts, I. M., Coffey, D. G., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aal2568 · Cited by 61
Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma
Elsegood, C. L., Tirnitz‐Parker, J. E. E., Olynyk, J. K., & Yeoh, G. C. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.47 · Cited by 63
Metabolic Regulation of CAR T Cell Function by the Hypoxic Microenvironment in Solid Tumors
Schurich, A., Magalhaes, I., & Mattsson, J. (2019) · Immunotherapy · doi:10.2217/imt-2018-0141 · Cited by 62
Wolski, D., Foote, P. K., Chen, D. Y., Lewis‐Ximenez, L. L., Fauvelle, C., Aneja, J., Walker, A., Tonnerre, P., Torres-Cornejo, A., Kvistad, D., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.006 · Cited by 60
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
Cid, L. L., Roessner, P. M., Chapaprieta, V., Öztürk, S., Roider, T., Bordas, M., Ízcue, A., Colomer, D., Dietrich, S., Stilgenbauer, S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01198-1 · Cited by 64
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Poggi, A. D., & Zocchi, M. R. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.016 · Cited by 58
Wilson, T. L., Kim, H., Chou, C., Langfitt, D. M., Mettelman, R. C., Minervina, A. A., Allen, E. K., Métais, J., Pogorelyy, M. V., Riberdy, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1508 · Cited by 58
Defining nervous system susceptibility during acute and latent herpes simplex virus-1 infection
Menendez, C. M., & Carr, D. J. J. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.02.020 · Cited by 60
He, R., Yang, X., Liu, C., Chen, X., Wang, L., Xiao, M., Ye, J., Wu, Y., & Ye, L. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.3 · Cited by 60
Hartana, C. A., Bergman, E. A., Broomé, A., Berglund, S., Johansson, M., Alamdari, F. I., Jakubczyk, T., Huge, Y., Aljabery, F. A.-S., Palmqvist, K., et al. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13183 · Cited by 62
Tomé, M., Pappalardo, A., Soulet, F., López, J. J., Olaizola, J., Léger, Y., Dubreuil, M., Mouchard, A., Fessart, D., Delom, F., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0086 · Cited by 60
Kim, Y., Lee, J., Jeong, W. K., Kim, S. T., Kim, J., Hong, J. Y., Kang, W. K., Kim, K., Sohn, I., & Choi, D. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01124-x · Cited by 61
Li, R., Liu, H., Cao, Y., Wang, J., Chen, Y., Qi, Y., Lv, K., Liu, X., Yu, K., Lin, C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0813-y · Cited by 62
Systemic inhibition of PTPN22 augments anticancer immunity
Ho, W. J., Croessmann, S., Lin, J., Phyo, Z. H., Charmsaz, S., Danilova, L., Mohan, A. A., Groß, N., Chen, F., Dong, J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146950 · Cited by 59
p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells
Janelle, V., Neault, M., Lebel, M., Sousa, D. M. D., Boulet, S., Durrieu, L., Carli, C., Muzac, C., Lemieux, S., Labrecque, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.698565 · Cited by 60
Su, G.-H., Xiao, Y., Jiang, L., Zheng, R., Wang, H., Chen, Y., Gu, Y., You, C., & Shao, Z.-M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03688-x · Cited by 61
Cheng, M., Liang, G., Zongyi, Y., Lin, X., Sun, Q., & Liu, Y. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04498-w · Cited by 59
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications
Chi, X., Luo, S., Ye, P., Hwang, W., Cha, J., Yan, X., & Yang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104771 · Cited by 62
Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors
Zhong, W., Xiao, Z., Qin, Z., Yang, J., Wen, Y., Yu, Z., Li, Y., Sheppard, N. C., Fuchs, S. Y., Xu, X., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2220 · Cited by 63
The mRNA-LNP vaccines – the good, the bad and the ugly?
Igyártó, B. Z., & Qin, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336906 · Cited by 61
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Qin, X., Ning, W., Liu, H., Liu, X., Luo, W., & Xia, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.027 · Cited by 62
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 69
Guo, X.-Z. J., Dash, P., Calverley, M., Tomchuck, S. L., Dallas, M. H., & Thomas, P. G. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2015.54 · Cited by 59
Tassi, E., Grazia, G., Vegetti, C., Bersani, I., Bertolini, G., Molla, A., Baldassari, P., Andriani, F., Roz, L., Sozzi, G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1387 · Cited by 57
Molecular Dissection of CD8 + T-Cell Dysfunction
Wang, C., Singer, M., & Anderson, A. C. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.008 · Cited by 60
Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult
Loftus, T. J., Mohr, A. M., & Moldawer, L. L. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000395 · Cited by 58
Drug response to PD-1/PD-L1 blockade: based on biomarkers
Chen, Q., Li, T., & Yue, W. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s168313 · Cited by 59
Genetic susceptibility to EBV infection: insights from inborn errors of immunity
Tangye, S. (2020) · Human Genetics · doi:10.1007/s00439-020-02145-3 · Cited by 48
Muliaditan, T., Halim, L., Whilding, L. M., Draper, B., Achkova, D., Kausar, F., Glover, M., Bechman, N., Arulappu, A., Sanchez, J., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100457 · Cited by 59
The MAPK dual specific phosphatase (DUSP) proteins: A versatile wrestler in T cell functionality
Sun, F., Yue, T.-T., Yang, C.-L., Wang, F.-X., Luo, J.-H., Rong, S.-J., Zhang, M., Guo, Y., Xiong, F., & Wang, C.-Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107906 · Cited by 59
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
Metadata
- Authors
- Wherry, E. J., & Kurachi, M.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Wherry, E. John
- Kurachi, Makoto
- Venue
- Nature Reviews Immunology
- Published
- 2015-07-24
- Volume
- 15
- Issue
- 8
- Pages
- 486-499
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC4889009
- OpenAlex
- W1910012553
- Cited by
- 4,652
- References
- 156
- Citations by year
- 2026: 563 · 2025: 494 · 2024: 518 · 2023: 508 · 2022: 517 · 2021: 551 · 2020: 441 · 2019: 381 · 2018: 306 · 2017: 227 · 2016: 129 · 2015: 12
- FWCI
- 21.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (HHSN266200500030C)
- National Institute of Allergy and Infectious Diseases (HHSN266200500030C, AI 082630, R01AI105343, AI095608, AI105343, AI112521, P01AI112521, U01AI095608, U19AI082630)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- T cell exhaustion, chronic viral infection, cancer immunotherapy, inhibitory receptors, persistent antigen, inflammatory signals, transcriptional programs, therapeutic target
- MeSH terms
- Bacterial Infections, Gene Expression Regulation, Humans, Immunologic Memory, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Cytotoxic, Transcription, Genetic, Virus Diseases, Signal Transduction, Cytokines, Clonal Anergy, CD57 Antigens, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
